company background image
DWTX logo

Dogwood Therapeutics NasdaqCM:DWTX Stock Report

Last Price

US$4.16

Market Cap

US$5.9m

7D

0.7%

1Y

-67.7%

Updated

30 Oct, 2024

Data

Company Financials +

Dogwood Therapeutics, Inc.

NasdaqCM:DWTX Stock Report

Market Cap: US$5.9m

DWTX Stock Overview

A development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.

DWTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Dogwood Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dogwood Therapeutics
Historical stock prices
Current Share PriceUS$4.16
52 Week HighUS$26.00
52 Week LowUS$2.50
Beta1.58
11 Month Change-2.12%
3 Month Change-19.22%
1 Year Change-67.71%
33 Year Change-97.15%
5 Year Changen/a
Change since IPO-99.00%

Recent News & Updates

Recent updates

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Aug 24
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

May 11
Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

Virios Therapeutics slides 11% postmarket on proposed stock offering

Sep 19

Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07

Aug 11

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jun 25
Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Mar 09
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Nov 02
Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jul 19
Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Jun 04

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Mar 31
Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Feb 01

Virios Therapeutics prices IPO at $10

Dec 17

Shareholder Returns

DWTXUS BiotechsUS Market
7D0.7%0.5%0.5%
1Y-67.7%24.7%36.8%

Return vs Industry: DWTX underperformed the US Biotechs industry which returned 27% over the past year.

Return vs Market: DWTX underperformed the US Market which returned 38.6% over the past year.

Price Volatility

Is DWTX's price volatile compared to industry and market?
DWTX volatility
DWTX Average Weekly Movement19.7%
Biotechs Industry Average Movement9.6%
Market Average Movement6.1%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: DWTX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: DWTX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20124Greg Duncanwww.dwtx.com

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.

Dogwood Therapeutics, Inc. Fundamentals Summary

How do Dogwood Therapeutics's earnings and revenue compare to its market cap?
DWTX fundamental statistics
Market capUS$5.94m
Earnings (TTM)-US$4.68m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DWTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$4.68m
Earnings-US$4.68m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.51
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did DWTX perform over the long term?

See historical performance and comparison